Outstanding Recoveries

• Home
• Outstanding Recoveries

Verdicts & Settlements

• 

  $3.2 Billion Settlement – Tyco International Securities Litigation

  In re Tyco International Ltd., Securities Litigation, MDL 1335 (D.N.H.)

  See More

  Milberg served as Co-Lead Counsel in this litigation, which involved federal securities claims against Tyco and its former CEO, CFO, general counsel, and certain former directors arising out of alleged insider trading and the overstatement of billions of dollars in income. In 2007, the court approved a $3.2 billion settlement.
• 

  $7.5 Million Settlement – Meritage Homes of the Carolinas, Inc. v. Town of Holly Springs

  Meritage Homes of the Carolinas, Inc. v. Town of Holly Springs, Wake Co. File No. 20-CVS-14511 (NC)

  See More

  $7.5 million class settlement on behalf of developers for illegal recreation fees in lieu of land dedication.
• 

  $138 Million Settlement – Biovail Corp. Securities Litigation

  In re Biovail Corp. Securities Litigation, No. 03-8917 (S.D.N.Y.)

  See More

  Milberg, representing Local 282 Welfare Trust Fund and serving as Co-Lead Counsel, litigated this securities action alleging that defendants made misleading statements concerning Biovail’s financial results and its drug, Cardizem LA. Following substantial discovery, including depositions across the U.S. and Canada, Milberg obtained a $138 million settlement for the class, and Biovail agreed to institute significant corporate governance changes.
• 

  $2.4 Billion Settlement – ACTOS Antitrust Litigation

  In re Actos End Payor Antitrust Litigation, Case No. 1:13-cv-09244 (U.S. District Court for the Southern District of New York)

  See More

  Milberg attorneys played a significant role in this litigation, including appointment to the MDL Discovery Committee, which accused Takeda Pharmaceuticals of failing to warn patients of the risks of bladder cancer, heart failure and other side effects associated with the Type 2 diabetes drug. In 2015, roughly 9,000 claims were settled for $2.4 billion and significant injunctive relief.
• 

  $3.4 Billion Settlement – Avandia Marketing, Sales Practices, and Products Liability Litigation

  In re Avandia Marketing, Sales Practices, and Products Liability Litigation, MDL 1871 (U.S. District Court for the Eastern District of Pennsylvania)

  See More

  Milberg attorneys were appointed to the Plaintiffs Steering Committee and served on the Discovery and Media Sub-Committees on behalf of thousands of patients who took the Type 2 diabetes drug Avandia, alleging the manufacturer failed to disclose the known and increased risk of heart attack and cardiac death. GlaxoSmithKline set aside $3.4 billion in 2011 to settle lawsuits.